PARIS, Jan. 27, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today its participation in the commemoration of the 50th anniversary of diplomatic relations between France and the People's Republic of China. In supporting the celebration, Sanofi affirms its commitment to economic development and public health in China.
"As one of the first multinational pharmaceutical companies to operate in China, Sanofi has continually provided innovative healthcare solutions for patients, expanding in pace with the country's development," said Christopher A. Viehbacher, Chief Executive Officer, Sanofi. "Our expanding portfolio of medicines and vaccines allows us to contribute to important public health issues in China, such as chronic disease management, prevention and food safety."
As one of the commemoration's major sponsors, Sanofi will participate in scientific events throughout the year in France and China, which will include Chinese students from select academic institutions in France. Sanofi also plans to participate in the "Better Healthcare" conference in Beijing with "Club Santé Chine", an initiative by the French government to help small and medium enterprises export healthcare products.
China is a showcase for Sanofi's collaborative approach, with many research and development agreements signed in the past six years, including in the areas of cancer, stem cells, diabetes and aging diseases. Sanofi partners include Shanghai Institutes for Biological Sciences, the Tianjin Institute of Hematology and Peking University. In recognition of the richness of China's research ecosystem, Sanofi settled management of its Asia-Pacific research and development activities in China in 2011.
About Sanofi in China
Present in China since 1982, Sanofi is committed to the treatment of chronic diseases, including through programs on diabetes, cardiovascular diseases and rare diseases. The Group has 11 regional offices and seven factories producing medicines, vaccines, animal health and consumer health products. As a global leader in consumer healthcare, Sanofi signed a joint venture with Minsheng in 2010 and acquired BMP Sunstone in 2011. Sanofi generated € 1.2 billion in revenues in China in 2012, and employs 8,500 people.
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
|Relations Presse||Relations Investisseurs|
|Laurence Bollack||Sébastien Martel|
|Tel +33 (1) 53 77 46 46||Tel +33 (1) 53 77 45 45|
PDF Version http://hugin.info/152918/R/1757142/593602.pdf